孟鲁司特对中重度稳定期慢性阻塞性肺疾病的临床疗效

Clinical Effect of Montelukast on Chronic Obstructive Pulmonary Disease in Moderate-severe Stable Period

目的:研究孟鲁司特对中重度稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的临床治疗效果。方法:选取选取2015年1月-2017年12月本院收治的60例中重度稳定期COPD患者临床资料进行分析,按照随机对数字表法分成对照组与观察组,每组30例。对照组给予信必可都保进行治疗,观察组在对照组治疗基础上增加孟鲁司特治疗,比较两组治疗效果。结果:观察组FEV_1、FEV_1%、FEV_1/FVC明显优于对照组,观察组呼吸困难和6-MWD评分明显优于对照组,差异均有统计学意义(P<0.05)。观察组不良反应发生率10.00%与对照组6.67%比较,差异无统计学意义(P>0.05)。结论:中重度稳定期COPD患者在常规治疗时联合孟鲁司特,疗效更为显著,值得推广应用。

Objective：To study the clinical effect of Montelukast on COPD in moderate-severe stable period.Method：A total of 60 patients with moderate-severe stable period COPD in our hospital from January 2015 to December 2017 were randomly divided into control group and observation group according to table of random numbers,30 patients in each group.The control group was treated with Symbicort,and observation group was treated with Montelukast on the basis of the control group.The treatment effects were compared between the two groups.Result：After treatment,the FEV1,FEV1% and FEV1/FVC of the observation group were significantly better than those of the control group,the dyspnea and 6-MWD scores of the observation group were significantly better than those of the control group,the differences were statistically significant（P〈0.05）.There was no significant difference of incidence of adverse reactions between the observation group 10.00% and the control group 6.67%（P〈0.05）.Conclusion：The effect of conventional treatment combined with Montelukast is significant in patients with moderate-severe stable period COPD,it is worth promoting the application.